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Objectives: The study objectives were to evaluate the safety, effectiveness, and
hemodynamic performance of a new stented bovine pericardial aortic valve.
Methods: This trial enrolled patients with symptomatic moderate or severe aortic
stenosis or chronic, severe aortic regurgitation. We assessed death, valve-related
adverse events, functional recovery, and hemodynamic performance at discharge,
3 to 6 months, and 1 year, as required by the US Food and Drug Administration for
regulatory approval. The primary analysis compared late linearized rates of
valve-related adverse events after implantation with Food and Drug
Administration–specified objective performance criteria to determine whether
the adverse event rates associated with the valve are within acceptable limits.
Adverse events included thromboembolism, thrombosis, all and major
hemorrhage, all and major paravalvular leak, and endocarditis.
Results: The primary analysis included 864 patients who received an implant and
904.1 valve-years of follow-up. A total of 577 patients completed the 1-year
evaluation. The primary end point was met for death, thromboembolism,
thrombosis, all and major paravalvular leak, and endocarditis, but not for all
and major hemorrhage. At 1 year, freedom from all death and from
valve-related death was 96.4% and 99.7%, respectively. From baseline to
1 year, New York Heart Association class changed as follows: I, 10.8% to
73.7%; II, 48.9% to 22.6%; III, 38.0% to 3.5%; and IV, 2.3% to 0.2%. Effective
orifice area increased from 0.9  0.5 to 1.5  0.4 (P<.0001), and mean aortic
gradient decreased from 42.7  16.5 to 12.5  4.3 (P<.0001).
Conclusions: This analysis of a new stented bovine pericardial aortic valve
demonstrated low overall mortality and valve-related adverse events, and
hemodynamic performance comparable to that of other surgical aortic valves.
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This analysis of a novel stented bovine aortic
valve demonstrated low overall mortality
and valve-related AEs, and hemodynamic
performance comparable to that of other
surgical aortic valves.Perspective
TheAvalus (Medtronic,Minneapolis,Minn)valve
has an excellent safety profile and favorable clin-
ical outcomes andhemodynamics through thefirst
year after implantation. For all valve-related AEs
except all and major hemorrhage, the valve per-
formedwell. The unexpected linearized late hem-
orrhage rates are likely due to preexisting patient
conditions requiring anticoagulation and the
length of follow-up.See Editorial Commentary page 1378.
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During the past several decades, there has been continued
improvement in aortic bioprosthetic valve design to
improve valve longevity, ease implantation, reduce
transvalvular gradients, decrease thrombogenicity, and aid
in later valve-in-valve transcatheter replacement. The
Avalus aortic valve bioprosthesis (Medtronic, Minneapolis,
Minn) was developed to continue this evolution in aortic
tissue valve design. It is a trileaflet, stented, low-profile,
bovine pericardial valve with a flexible sewing cuff, a
polyester-covered, barium sulfate–impregnated base frame,
and alpha amino oleic acid–treated, laser-cut leaflets. The
safety and clinical and hemodynamic performance of this
novel bioprosthesis are being evaluated in the PERIcardial
SurGical AOrtic Valve ReplacemeNt (PERIGON) Pivotal
Trial for the Avalus valve, a prospective, nonrandomized,
international study. Early results from this trial
demonstrated a good safety profile and hemodynamic
performance, although bleeding rates exceeded objective
performance criteria (OPC).1 This article reports data
from a larger cohort of patients with 1 year of follow-up.MATERIALS AND METHODS
Study Design
The trial enrolled patients with symptomatic moderate or severe aortic
stenosis or chronic, severe aortic regurgitation to receive a new bovine
stented aortic valve. The trial design was based on recommendations of
the US Food and Drug Administration and the International Organization
for Standardization for cardiac valve prostheses to fulfill requirements
for regulatory approval.2,3 The trial was conducted at 19 sites in the
United States, 13 sites in Europe, and 4 sites in Canada (Table E1).The Journal of Thoracic and CarDevice Description
The Avalus bioprosthesis is indicated for the replacement of a diseased,
damaged, or malfunctioning native or prosthetic aortic valve. It comprises a
polyester-covered base frame and trileaflet support frame that are
injection-molded using a polyetheretherketone material. The base frame
contains barium sulfate for radiographic visualization. The laser-cut
leaflets consist of bovine pericardial tissue cross-linked in buffered
glutaraldehyde. The valve is treated with alpha amino oleic acid to
mitigate calcification.4 The base frame cover contains a polyester sewing
ring with markers for suturing and for seating the valve in the
supra-annular position. The valve is available in sizes of 17, 19, 21, 23,
25, 27, and 29 mm.
Patient Selection
Inclusion criteria. Patients with moderate or greater aortic stenosis
or regurgitation with a clinical indication for aortic valve replacement
(AVR) were considered for participation in the study. Concomitant
procedures were allowed, but were limited to left atrial appendage ligation,
coronary artery bypass graft, closure of a patent foramen ovale, ascending
aortic aneurysm or dissection repair not requiring circulatory arrest, and
resection of a subaortic membrane not requiring myectomy. These
limitations were recommended by regulatory agencies and went into effect
after the first 120 patients were enrolled.
Exclusion criteria. Patients were excluded for preexisting
prosthetic valve or annuloplasty device; need for replacement or
repair of the mitral, pulmonary, or tricuspid valve; previous
implant and explant of study valve; active endocarditis, myocarditis,
or other systemic infection; anatomic abnormality that increased
surgical risk of morbidity or mortality (ie, ascending aortic
aneurysm or dissection repair requiring circulatory arrest, acute type
A aortic dissection, ventricular aneurysm, porcelain aorta, hostile
mediastinum, hypertrophic obstructive cardiomyopathy, documented
pulmonary hypertension [systolic >60 mm Hg]); noncardiac major/
progressive disease with life expectancy of less than 2 years;
renal failure (defined as dialysis therapy or glomerular filtration rate
<30 mL/min/1.73 m2); hyperparathyroidism; participation in
another investigational trial or observational study; pregnant, lactating,
or planning pregnancy during the trial period; documented history
of substance abuse; greater than mild mitral valve or tricuspid valve
regurgitation on echocardiography; systolic ejection fraction less than
20% on echocardiography; grade IV diastolic dysfunction;
documented bleeding diatheses; prior acute preoperative neurologic
deficit or myocardial infarction without return to baseline or
stabilization 30 days or more before enrollment; or need for emergency
surgery.
Procedure
Surgeons were allowed to use their preferred surgical approach for
AVR, which included median sternotomy (79.4%), hemisternotomy
(13.7%), right thoracotomy (5.4%), and other techniques (1.5%).
Cardioplegia and cardiopulmonary bypass strategies were also left to the
surgeon’s discretion. Supra-annular (84.3%) positioning of the valve was
recommended by the manufacturer, but intra-annular (14.9%), subannular
(0.6%), and other (0.2%) positions were allowed. The most common
suturing techniques were noneverting mattress sutures (49.0%) and
simple interrupted sutures (29.9%). Pledgets were used in 54.4% of
patients. Postoperative anticoagulation per local institutional practice
was recommended.
Primary End Points
The primary safety end points were death and valve-related
thromboembolism, thrombosis, hemorrhage, paravalvular leak (PVL),
endocarditis, hemolysis, structural valve deterioration, nonstructuraldiovascular Surgery c Volume 156, Number 4 1369
TABLE 1. Baseline characteristics and comorbidities
Characteristic Patients (N ¼ 864)
Age, y 70.4  8.9
Male (%) 644 (74.5)







Mortality 2.0  1.4
Morbidity or mortality 14.8  6.0
Angina (%) 329 (38.1)
Chronic obstructive pulmonary disease (%) 109 (12.6)
Congestive heart failure (%) 183 (21.2)
Coronary artery disease (%) 364 (42.1)
Diabetes mellitus (%) 227 (26.3)
Dyslipidemia (%) 517 (59.8)
Hypertension (%) 658 (76.2)
Left ventricular hypertrophy (%) 341 (39.5)
Myocardial infarction (%) 73 (8.4)
Peripheral vascular disease (%) 67 (7.8)
Renal dysfunction/insufficiency (%) 89 (10.3)
Stoke/cerebrovascular accident (%) 31 (3.6)
Transient ischemic attack (%) 45 (5.2)
Previous percutaneous coronary intervention (%) 125 (14.5)
Previous percutaneous valvuloplasty (%) 1 (0.1)
Implanted pacemaker (%) 24 (2.8)
Implanted defibrillator (%) 2 (0.2)




dysfunction, reintervention, and explant.5 Effectiveness was assessed by
New York Heart Association (NYHA) functional classification and
hemodynamic performance. Hemodynamic performance included
effective orifice area (EOA), EOA index (EOAI), peak pressure gradient,
mean pressure gradient, valvular regurgitation, cardiac output, and cardiac
index. The protocol calls for evaluations to be performed at baseline
(ie, preoperative visit), time of implant, and discharge up to 30 days, 3 to
6 months, and 1 year. Baseline evaluations were completed within
45 days of the scheduled implant procedure except transthoracic
echocardiography, which was completed within 90 days before the
procedure. Follow-up will continue annually through 5 years with
telephone contacts at 18 and 30 months. Table E2 details the information
collected at each visit. New pacemaker implantation rate was not a defined
end point in the study; however, these data were collected as reported treat-
ments on adverse event (AE) forms when applicable. Patients in whom
implantation of the study valve was attempted but not completed were
followed for 30 days for safety reporting and then exited from the study.
Statistical Analysis
The analysis for this article was performed when the study accumulated
800 valve-years of follow-up. The safety objective was assessed by
comparing linearized late valve-related AE rates from patients who
received the study valve to acceptable linearized valve-related AE rates
(ie, OPC) as defined by the Food and Drug Administration (Table E3).2,3
The primary hypothesis was that the true linearized AE rate for the study
valve would be significantly less than or equal to twice the OPC
(2 3 OPC) for commercial bioprosthetic heart valves. The sample size
estimation was based on the methods of Grunkemeier and colleagues,6
who determined that the amount of data required to test the null hypothesis
using the smallest acceptable AE rate (1.2% per valve-year, excluding
valve thrombosis, major hemorrhage, and major PVL) was 800
valve-years. This estimation assumes a 95% confidence level, a power of
0.80, and an annual attrition rate of 5%.
For categoric variables, the number and percentage of patients are
presented. For continuous variables, the means and standard deviations
are presented. Survival was analyzed using the Kaplan–Meier method.
Paired analyses were also performed for hemodynamic and effectiveness
end points, and t tests were used to compare hemodynamic endpoints at
baseline and 1 year. For NYHA class, the chi-square or Fisher exact test
was used as applicable. P<.05 was considered statistically significant.Previous aortic valve repair (%) 2 (0.2)
Previous aortic valve implant (%) 6 (0.7)
Rhythm on 12-lead electrocardiogram (%)*
Sinus 693 (80.5)
Pacing 19 (2.2)
Atrial fibrillation 35 (4.1)
Other 114 (13.2)
Atrioventricular block (%)* 110 (12.8)
Left bundle branch block (%)* 27 (3.1)
Right bundle branch block (%)* 88 (10.2)
Values are n (%) or mean standard deviation. NYHA, New York Heart Association;
STS, Society of Thoracic Surgeons. *N ¼ 861 for electrocardiogram measures.RESULTS
Patients
From May 12, 2014, to June 30, 2016, 962 consecutive
patients were enrolled. Seven patients did not complete the
baseline evaluation, and 1 died. Ninety-seven patients with-
drew before valve implantation. Of these, 64 withdrawals
occurred before the procedure (12 patients withdrew consent,
28 were withdrawn by their physician, and 24 withdrew for
‘‘other’’ reasons). Thirty-three withdrawals occurred at the
time of the procedure (29 patients did not receive the study
valve, 3 patients were withdrawn by their physician, and 1
withdrew for an ‘‘other’’ reason). The most common reason
for withdrawal before or during the procedure was the need
for an unallowed concomitant procedure. A total of 864
patients received the study valve, and 577 have completed
1 year of follow-up (Figure E1). The number of total
valve-years was 904.1 and late valve-years was 834.2.
Mean age was 70.4  8.9 years, and 74.5% of patients
were male. Eighty-seven percent of patients had a baseline1370 The Journal of Thoracic and Cardiovascular SurNYHA classification of II or III. The most common comor-
bid conditions were hypertension (76.2%), dyslipidemia
(59.8%), and coronary artery disease (42.1%) (Table 1).
The primary indication for AVR was aortic stenosis for
85.4% of patients (n ¼ 738), aortic regurgitation for











































FIGURE 1. Kaplan–Meier estimates of freedom from all, cardiac, and






















































FIGURE 2. Late linearized rates of valve-related AEs (vertical blue bars)
compared with 2 times the OPC (red horizontal bars). The vertical blue
lines indicate the 95% upper confidence limits of the linearized late event
rates. Late events occurred more than 30 days postimplant.OPC, Objective
performance criteria; PVL, paravalvular leak.






for 8.6% of patients (n¼ 74), and a failed bioprosthesis for
0.7% of patients (n ¼ 6).
Procedure
The mean cardiopulmonary bypass time was
105.0  42.3 minutes (89.0  30.8 minutes for isolated
AVR and 120.5  46.1 minutes for AVR with concomitant
procedures). The mean crossclamp time was
79.0  31.9 minutes (65.7  23.2 minutes for isolated
AVR and 91.9  33.8 minutes for AVR with concomitant
procedures). Coronary artery bypass grafting was the
most common concomitant procedure (32.5%) (Table E4).
Safety End Points
Early events (30 days). Early mortality occurred in 10
patients (1.2%). The Kaplan–Meier estimates of freedom
from all-cause, cardiac, and valve-related mortality at
30 days were 98.7%, 99.5%, and 100%, respectively
(Figure 1). Fourteen (1.6%) early hemorrhage events
occurred in 13 patients, and of these, 8 (0.9%) were major
events occurring in 8 patients. There were 12 (1.4%) early
thromboembolic events in 11 patients. Eight (0.9%) of the
thromboembolic events resulted in a stroke, and 4 (0.5%)
resulted in a transient ischemic attack. At 30 days, PVL
was classified as none/trace in 763 patients (94.8%,
n¼ 849), mild in 15 patients (1.8%), moderate in 0 patients
(0.0%), and severe in 0 patients (0.0%). Early endocarditis
occurred in 2 patients (0.2%), nonstructural valve
deterioration occurred in 2 patients (0.2%), and valve-
related reintervention occurred in 3 patients (0.3%). Valve
explant was required in 3 patients (0.3%) because of
endocarditis. There were no occurrences of early valve
thrombosis, hemolysis, or structural valve deterioration.The Journal of Thoracic and CarLate events (>30 days). Late mortality occurred in 28
patients (3.4%). The Kaplan–Meier estimates of freedom
from all-cause, cardiac, and valve-related mortality at
1 year were 96.4%, 99.1%, and 99.7%, respectively. Thirty
late hemorrhagic events occurred in 28 patients; 21 were
major events occurring in 19 patients. There were 14
(1.7%) late thromboembolic events. Eight (1.0%) of the
thromboembolic events resulted in a stroke, and 6 (0.7%)
resulted in a transient ischemic attack. At 1 year, PVL
was classified as none/trace in 540 patients (96.1%,
n¼ 562), mild in 14 patients (2.5%), moderate in 3 patients
(0.5%), and severe in 0 patients (0.0%). Late endocarditis
occurred in 11 patients, nonstructural valve deterioration
occurred in 5 patients, and reinterventions occurred in 6
patients. There were 6 valve explants due to endocarditis.
There were no occurrences of late valve thrombosis,
hemolysis, or structural valve deterioration. A new
pacemaker was required by 33 of 864 patients (3.8%).
Eighty-seven patients who received the Avalus
bioprosthesis were aged less than 60 years at enrollment.
Ten of these patients had 11 valve-related AEs (Table E5).
Late linearized event rates. The 95% upper confidence
limits for the late linearized rates for valve-related AEs in
the primary analysis were all below the 2 3 OPC rates
except all and major hemorrhage (Figure 2). The late
linearized rate was 3.4% per valve-year for all death,
0.6% per valve-year for cardiac death, 0.5% per valve-year
for valve-related death, 1.7% per valve-year for
thromboembolism, 0.6% per valve-year for all PVL, 0%
per valve-year for major PVL, and 1.3% per valve-year
for endocarditis.
For all hemorrhage and major hemorrhage, the late
linearized rates were 3.6% and 2.5% per valve-year,
respectively, and the 95% upper bound of these ratesdiovascular Surgery c Volume 156, Number 4 1371




were 4.8% and 3.6% per valve-year, respectively. Both the
linearized rates and the upper bounds exceeded 2 times the
OPC rates of 2.8% and 1.8% per valve-year, respectively.
Of the 21 major hemorrhagic events, 17 occurred in patients
taking anticoagulants or antiplatelets for preexisting
conditions, 2 occurred in patients taking anticoagulants or
antiplatelets for new-onset atrial fibrillation, and 2 occurred
in patients taking anticoagulants or antiplatelet medications
for surgical AVR prophylaxis (Figure E2 shows additional
details). Table E6 lists the antiplatelet and anticoagulant
use of the study population to 1 year. The linearized late
hemorrhage rates were highest in patients taking
anticoagulants for preexisting conditions (Table E7).
The linearized late event rates for safety end points not
included in the OPC analysis were all very low: hemolysis,
0%; structural valve deterioration, 0%; nonstructural valve
dysfunction, 0.6%; reintervention, 0.7%; and explant,
0.7% per valve-year.Hemodynamic Results
Peak and mean aortic pressure gradients and mean EOA
improved substantially after implantation of the study
device, and these improvements were maintained at
1 year (Figure 3; P<.001 for all, baseline vs 1 year). The
peak aortic pressure gradient was 23.9  8.4 mm Hg at
discharge/30 days and 23.2  7.8 mm Hg at 1 year
(n ¼ 520). The mean aortic pressure gradient was
13.4  4.8 mm Hg at discharge/30 days and
12.5  4.4 mm Hg at 1 year (n ¼ 518). The mean EOA
was 1.6  0.4 cm2 at discharge/30 days and
1.5  0.4 cm2 at 1 year (n ¼ 394). The mean EOAI was
0.44  0.23 cm2/m2 at baseline, 0.81  0.19 cm2/m2 at
discharge/30 days, and 0.75  0.17 cm2/m2 at 1 year
(n ¼ 394; P < .001, baseline vs 1 year). At
discharge/30 days, 163 of 436 patients (37.4%) had no or


























































FIGURE 3. Paired analysis of mean aortic pressure gradient and EOA
from baseline (ie, preoperative visit) through 1 year. N ¼ 394 for EOA.
N ¼ 518 for mean gradient. Echocardiograms were adjudicated by core
laboratory.
1372 The Journal of Thoracic and Cardiovascular SurEOAI>0.85 cm2/m2), 195 patients (44.7%) had moderate
PPM (EOAI >0.65 to 0.85 cm2/m2), and 78 patients
(17.9%) had severe PPM (EOAI 0.65 cm2/m2). At
1 year, corresponding values were 107 (24.5%), 197
(45.2%), and 132 (30.3%), respectively. Table 2 presents
mean gradient, EOA, EOAI, and degree of PPM by visit
and valve size. Table 3 presents mean aortic gradient by
degree of PPM, visit, and valve size.
Cardiac output was 5.1  1.3 L/min at baseline,
5.1  1.2 L/min at discharge/30 days, and 4.5  1.0 L/min
at 1 year (P<.001, baseline vs 1 year). The cardiac index
was 2.6  0.7 L/min/m2 at baseline, 2.6  0.6 L/min/m2 at
discharge/30 days, and 2.3  0.5 L/min/m2 at 1 year
(P<.001, baseline vs 1 year).
Effectiveness End Points
Approximately three fourths of patients (73.6%) had
maintained improvement of 1 to 2 NYHA classes at
1 year; 1.7% had worsened by 1 class, and 23.2% had no
change in NYHA class at the same time point. At 1 year
of follow-up, 73.7% of patients had NYHA class I
functional status, 22.6% had class II, 3.5% had class III,
and 0.2% had class IV (Figure 4).
Regurgitation
At discharge/30 days, transvalvular regurgitation was
classified as none/trace in 96.9% of patients, mild in
2.9% of patients, moderate in 0.2% of patients, and severe
in 0.0% of patients. At 1 year, transvalvular regurgitation
was classified as none/trace in 96.9% of patients, mild in
3.1% of patients, moderate in 0.0% of patients, and severe
in 0.0% of patients. At discharge/30 days, PVL was
classified as none/trace in 97.8% of patients and mild in
2.1% of patients; there were no cases of moderate PVL at
this time point. At 1 year, PVL was classified as none/trace
in 96.5% of patients, mild in 2.3% of patients, and
moderate in 0.6% of patients. There were no cases of severe
PVL during 1 year of follow-up.
DISCUSSION
Principle Findings
This prospective, multicenter trial demonstrates the
safety and early clinical and hemodynamic performance
of the Avalus aortic valve bioprosthesis. There was
excellent early and 1-year survival, a low rate of
valve-related AEs, sustained improvement in NYHA
functional class, and excellent hemodynamic performance
of the Avalus valve. These data confirm earlier findings in
the PERIGON Pivotal Trial1 in a larger cohort of patients,
providing greater clarity on patient improvement and the
early safety and performance of this new bioprosthesis.
In this study, early mortality was 1.2%, and survival at
1 year was 96.4%. These results compare favorably to
those reported in the literature for both pericardialgery c October 2018
TABLE 2. Mean aortic pressure gradient and valve effective orifice area by visit and valve size
Visit
Valve size
All sizes17 mm 19 mm 21 mm 23 mm 25 mm 27 mm 29 mm
Mean aortic pressure gradient, mm Hg (n)














































Effective orifice area, cm2 (n)














































Effective orifice area index, cm2/m2 (n)

















































































































































PPM definitions: none, EOAI>0.85 cm2/m2; moderate, 0.65<EOAI  0.85 cm2/m2; and severe, EOAI 0.65 cm2/m2. NA, Not available; PPM, prosthesis–patient mismatch.






and porcine aortic valves. Bavaria and colleagues7
reported an early mortality of 1.8% and 1-year survival of
95.8% in a multicenter study of the St Jude Trifecta valve
(St Jude Medical, St Paul, Minn). Goldman and colleagues8
recently reported early mortality of 1.5% in their midterm
results of the Trifecta valve. Conte and colleagues9 reported
a 1-year survival of 92% in a multicenter assessment of the
Mitroflow aortic valve (LivaNova, London, UK). Likewise,
Fiegl and colleagues10 reported a 2.0% 30-day mortality
and 90.6% 1-year survival for the Edwards (Irvine, Calif)
Magna Ease valve. For the St Jude aortic porcine
Epic valve, Jamieson and colleagues11 reported an early
mortality of 3.6% and a linearized late mortality of 5.2%
per patient-year.The Journal of Thoracic and CarLikewise, the late linearized rates of AEs observed in
this study compare favorably with other contemporary
multicenter studies of pericardial aortic valves. Similar
late linearized rates with the Avalus valve were observed
with the Trifecta valve and the Mitroflow valve for
thromboembolism (1.7% vs 1.9% and 1.34% per
patient-year, respectively), PVL (0.6% vs 0.0% and
0.6%), major PVL (0.0% vs 0.0% and not available),
endocarditis (1.3% vs 1.07% and 1.4%), major
hemorrhage (2.5% vs 2.6% and not available), and
explant (0.7% vs 0.59% and not available).7,9 Similar to
the Trifecta valve, in this study there were no cases of
valve thrombosis or hemolysis. There were also no
cases of structural valve deterioration, compared withdiovascular Surgery c Volume 156, Number 4 1373
TABLE 3. Mean aortic gradient by prosthesis–patient mismatch and valve size
Degree
of PPM


















None 14.00 (1) 14.20  2.86 (5) 13.68  4.76 (34) 11.59  3.70 (96) 11.75  3.47 (80) 9.15  2.66 (27) 10.14  4.41 (7) 11.68  3.85 (250)
Moderate NA 19.58  5.35 (12) 15.42  4.36 (59) 13.43  4.16 (105) 12.54  3.45 (108) 11.42  4.30 (31) 8.50  0.71 (2) 13.50  4.36 (317)
Severe NA 19.85  6.66 (13) 17.09  5.98 (44) 14.71  5.06 (56) 15.55  3.97 (40) 14.29  4.75 (7) NA 15.98  5.37 (160)
1 y
None NA 14.00  2.83 (2) 11.72  2.70 (18) 9.35  2.92 (46) 10.40  3.78 (45) 8.00  2.13 (16) 9.80  3.11 (5) 9.95  3.30 (132)
Moderate NA 16.67  6.32 (9) 13.03  3.66 (33) 12.02  3.28 (102) 11.36  3.25 (84) 10.95  4.56 (20) NA 12.01  3.71 (248)
Severe 24.00 (1) 18.36  4.38 (14) 16.19  4.25 (48) 14.47  3.93 (53) 14.00  4.73 (38) 14.20  4.87 (5) NA 15.27  4.48 (159)
PPM definitions: none, EOAI>0.85 cm2/m2; moderate, 0.65<EOAI 0.85 cm2/m2; and severe, EOAI 0.65 cm2/m2. PPM, Prosthesis–patient mismatch; NA, not applicable.




very low rates reported for the Trifecta valve (0.12% per
patient-year) and the Mitroflow valve (0.21% per
patient-year).
The trial did not meet the expectation for bleeding,
because the upper bound of the 95% confidence interval
for both all hemorrhage and major hemorrhage was greater
than twice the OPC. Of note, the observed rate for major
hemorrhage in this trial of 2.5% per patient-year was
similar to that observed in the multicenter trial of the
St Jude Trifecta valve of 2.6% per patient-year. There are
several possibilities as to why the bleeding rate exceeded
expectations. As shown in Table E6, a large proportion of
patients were taking anticoagulants or antiplatelet
medications for preexisting conditions unrelated to valve
prophylaxis, whereas only 2 of the major bleeding events
were in patients taking anticoagulants for valve prophylaxis
(Table E7). Therefore, the majority of bleeding events were
likely related to the anticoagulation management of
preexisting conditions. In addition, this study analyzed the
1-year results of 577 of the 864 patients enrolled. Therefore,
the linearized rates are biased toward the early results of the
study. Because bleeding is more likely to occur early than
late, the linearized rates of hemorrhage may be artificially





































FIGURE 4. Paired analysis of NYHA from baseline (ie, preoperative
visit) through 1 year. N ¼ 566. NYHA, New York Heart Association.
1374 The Journal of Thoracic and Cardiovascular SurAt 1 year, EOAI was 0.65 cm2/m2 or less in 30.3% of
patients, more than 0.65 to 0.85 cm2/m2 or less in 45.2%
of patients, and more than 0.85 cm2/m2 in 24.5% of
patients. In general, the concern with PPM is high residual
postoperative gradients leading to reduced survival.
Although there was an increase in PPM as determined by
EOAI, there was no corresponding increase in clinically
significant mean aortic gradient. In the total trial population,
mean gradients are stable to slightly lower at 1 year in the
severe PPM group compared with baseline, and all but 1,
in a patient who received a 17-mm valve, remain below a
threshold of clinical significance (20 mm) (Table 3). A
subsequent analysis presented at the 2017 European
Association for Cardio-Thoracic Surgery conference
demonstrated that there has been no statistically
significant difference in outcomes between patients with
EOAI less than 0.75 cm2/m2 and those with EOAI
0.75 cm2/m2 or greater.12 An article on PPM is currently
in development.
In the PERIGON Pivotal Trial, the aortic stenosis was
relieved with minimal regurgitation observed at 1 year.
Moreover, the majority of subjects had improved NYHA
classification at follow-up; 75.0% of the patients improved
by at least 1 class at their 1-year visits. These data suggest
the clinical effectiveness after 30 days has been maintained.
Mean aortic gradient levels at 1-year follow-up were below
20 mm Hg for all groups (no PPM, moderate PPM, and
severe PPM) and lower than the mean aortic gradient
criteria defining moderate (20-39 mm Hg) or severe
(40 mm Hg) aortic stenosis in American College of
Cardiology/American Heart Association valvular heart
disease guidelines.13 The rates of valve-related death,
structural valve deterioration, nonstructural valve
dysfunction, reintervention, and explant were comparable
to the rates in the literature for other bovine surgical valves.
The majority of patients had sustained improvement in
NYHA functional class at 1 year. The observation that
97% of patients were in NYHA functional class I or II
compares favorably with that reported for the Trifecta and
the Mitroflow valves. This improvement in NYHA
functional class is due to the sustained decrease in aorticgery c October 2018






gradient and increase in EOA associated with the Avalus
valve. As expected, the mean aortic pressure gradients
decreased and EOAs increased as valve sized increased,
and compared favorably to other aortic valves.7-11
Study Limitations
Because of the study design, a portion of the 864 patients
who received an implant had not completed their 1-year
visit at the time that 800 valve-years of follow-up had
been reached. It is possible that some of those patients
were still in the early postoperative period and
receiving anticoagulation, posing a higher risk of bleeding
events. Given the long-term nature of studies of implantable
valve bioprostheses, the Food and Drug Administration
guidelines use a linearized assumption for analysis of key
valve-related events, but also define the threshold of
minimum length of follow-up required as 300 subjects at
1-year follow-up. We believe the 577 subjects who had
achieved at least 1 year of follow-up at the time of the analysis
provide sufficient evidence as to the early performance and
safety of the valve. Early bleeding events also may have
been influenced by the reduction in allowable concomitant
procedures after the first 120 patients were enrolled.
CONCLUSIONS
The findings of this study demonstrate that the Avalus valve
has an excellent safety profile and favorable clinical outcomes
and hemodynamics through the first year after implantation.
For all AEs except all and major hemorrhage, the Avalus
valve performed well, coming in below the prespecified event
rates. The unexpected linearized late hemorrhage rates are
likely due to preexisting patient conditions requiring
anticoagulation and the length of follow-up in this study.
Webcast
You can watch a Webcast of this AATS meeting
presentation by going to: https://aats.blob.core.windows.
net/media/17AM/2017-05-01/BallroomABC/05-01-17_Ball
roomABC_1630_Sabik.mp4.
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Discussion
Dr W. R. Chitwood (Greenville, NC).
Thank you, Dr Sabik, for a well-
organized and clear presentation of the
results of the PERIGON Pivotal Trial,
whichwas designed to evaluate theMed-
tronic Avalus bovine pericardial valve.
Bioprosthetic valves are now im-
planted in more than 80% of aortic valve
cases; moreover, the age limit continues to decrease. However,1376 The Jouno one has developed a Holy Grail valve that compares
favorably to the normal aortic valve. Issues of gradient, PVL,
and endocarditis have generally been solved, but long-term
durability remains the Gordian knot that is left to be untied
scientifically.
Dr Sabik, you have shown us 1-year data from this
pivotal trial that evaluated this pericardial valve. The
comparative pericardial aortic surgical valves to date are
the Edwards Magna Ease, with the predicate being the
Perimount valve; the St Jude, now Abbott, Trifecta valve;
and the Sorin, now LivaNova, Mitroflow valve. Each of
these is designed for supra-annular implantation that has
been shown to have advantages over porcine stented valves
as far as gradient and, in most cases, durability. The
Mitroflow and Trifecta valves are structurally different
than the Avalus or the Magna Ease valve as far as the
attachment location of the leaflets. The Magna Ease and
Avalus valves have similar leaflet structure, but the frames
and manner of fixation are a bit different.
You and your colleagues wrote an article in The Annals
of Thoracic Surgery in 2015 that perhaps showed the
longest follow-up and the largest series, and that is
12,569 implants between 1982 and 2011 for the Perimount
Edwards pericardial valve. The mean age was 70 years,
and the explants for structural valve deterioration were
1.9% and 15% at 10 and 20 years. In patients aged less
than 60 years, the comparative explant data were 5.6%
and 46% for structural valve deterioration, respectively,
in other words, much higher for patients who are aged
less than 60 years. To this end, we would expect that the
Magna Ease valve should have similar results or better.
The new version of the Magna Ease valve, the Resilia,
seems to be the best comparator, as 1-year data were
presented last year for the COMMENCE trial. So we are
comparing valves with 1 year versus 1 year.rnal of Thoracic and Cardiovascular SurThe PERIGON pivotal trial was a nonrandomized
prospective multi-institutional and international clinical
trial that enrolled 864 patients, but the basis for the study
was 577 patients with 1-year data. You presented these
data nicely, but also Dr Klautz had presented some of the
data earlier in Barcelona at the 2016 European Meeting.
What is the difference in this part of the trial and what
Dr Klautz presented last year?
Dr Joseph F. Sabik (Cleveland, Ohio).
Obviously we have more patients and
longer follow-up and therefore more
data. In looking at why it was divided
into 2, obviously the requirements for
the Conformite Europeene mark are
less than the Food and Drug
Administration mark. So we thought
we would look at the data at the time of submitting forgery c October 201Conformite Europeene mark as well as submitting for
Food and Drug Administration approval. So, again, this
study has more patients enrolled and longer follow-up.
DrChitwood.As Imentioned, themost recent comparative
trial was the Edwards COMMENCE trial. It was presented last
year at the American Association for Thoracic Surgery annual
meeting. The 1-year results were virtually the same with the
exception that the PERIGON trial showed a slightly higher
transvalvular gradient at 2 torr and a 0.2 cm2 lower EOA but
substantially higher hemorrhage rates. These 2 issues were
concerning. I think you have tried to explain why the
hemorrhage rates are higher, but it is still concerning. Did
you find the hemorrhage rate was related to the valve or was
it related to preexisting conditions and a number of
patients were in atrial fibrillation and on anticoagulation
medication?
Dr Sabik.We can’t be sure, but that was our impression.
As you pointed out, not all 800 patients have reached the
1-year mark. The outcomes of the study are still biased
toward the early outcomes, and we know that most bleeding
tends to occur within the first 6 months. Second, when we
looked at the actual patients who bled, most of them bled
who were on anticoagulants or antiplatelet agents for other
reasons not related to the valve.
It is hard to be sure, but again, our impression was that
patients who were on anticoagulants for valve prophylaxis,
the bleeding rate was very low, but the bleeding tended to
occur in patients on anticoagulants for preexisting conditions.
Dr Chitwood. So bleeding did not seem to be related to
the valve?
Dr Sabik. We don’t think it’s related to the valve,
correct.
Dr Chitwood. Compared with this new Edwards Resilia
valve, you had slightly higher gradients. This was not a
tremendous difference at 2 torr, but everybody is concerned
about gradients especially with the low gradient TAVR
valves. Does this amount of increased gradient matter?8






Why do you think therewould be a difference between these
2 valves? They seem to be constructed similarly.
Dr Sabik. There probably are many similar things, but
there are some things that are specific to this valve. Is there
a difference between 13 and 15 or 14 and 16, you know,
probably not, at least not clinically.
But there were specific design features to this valve.
Obviously the leaflets are attached inside the stent. The
leaflets are made in a certain way; there are precision needle
holes to where they are sewn to reduce stress. These were
done to increase valve durability. As you said, you are
always kind of focused on getting the best hemodynamic
results with the same long-term durability, and our hope
was with this design that we would have better long-term
durability. But again, we are only going to know that over
time. Maybe that might result in a 1- or 2-mm increase in
gradient, but whether that matters or not, I don’t believe it
will be clinically significant.
Dr Chitwood. As in other pericardial valves, your data
clearly show that with time, the gradient does decrease.
Did you have any patient–prosthetic mismatches, because
23% of your patients had a size 19 or 21 valve implanted?
Dr Sabik. Yes, there were some, and I apologize, it is in
the article, but I don’t know the number right offhand.
Dr Chitwood. What about the pacemaker implantation
rate for this valve?
Dr Sabik. I’m sorry, I don’t know that information either.
I will find that out.
Dr Chitwood. Your data were well presented. You
always do a great job.
Dr J. M. DiMaio (Dallas, Tex). Dr Sa-
bik, can you talk about the treatment of
the leaflets, anything different
about that? You mentioned various
characteristics of the frame.The Journal of Thoracic and CarDr Sabik. They are laser-cut leaflets and treated
with alpha amino oleic acid to prevent calcification.
One of the things that is remarkable is that there
were no early structural valve failures, because the
other valves have shown a bit of structural valve
failure even early. One of the things that was done
was looking at the stresses across the leaflet, and
the holes for where the valve is sutured in place
were figured out mathematically ahead of time to
reduce stress on the leaflets. So it is one of the things
that is a bit different. The stent design is probably a
little more rigid, again, so we don’t get the posts
creeping in resulting in early aortic insufficiency. So
things are done, again, to improve durability.
Dr R. Shemin (Los Angeles, Calif).
Beautiful study, well presented, but I
am still struggling to understand where
you see the advantage of this valve over
the other valves that we currently have,
such as the Magna Ease as Ranny
Chitwood spoke about.diovascular SurgeDr Sabik. These are early data, and they show the safety
and clinical effectiveness of the valve, at least to 1 year. As I
mentioned, there were design things that we did to ease
implantation but also will help with the long-term durability
of the valve, obviously which you are only going to know
with time.
Dr Shemin. I think all of us are putting tissue valves in
younger patients. We are concerned about valve-in-valve
options when these valves ultimately fail. Has this valve
been designed in any way to facilitate a valve-in-valve
option? Is the valve’s annulus expandable to allow a larger
transcatheter AVR in the future?
Dr Sabik. The answer to that is yes, the stent
design is impregnated with barium to ease in radiographic
visualization of the valve if you were to do a valve-in-
valve.ry c Volume 156, Number 4 1377
FIGURE E1. CONSORT flow diagram detailing patient disposition from enrollment through 1 year of follow-up. LTFU, Lost to follow-up.
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FIGURE E2. Major bleeding events.
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TABLE E1. Study sites and principal investigators
Center name Site principal investigator
Deutsches Herzzentrum M€unchen Klinik an der TU M€unchen, M€unchen, Germany R€udiger Lange
Hôpital Haut-Levêque – CHU de Bordeaux, Pessac Cedex, Bordeaux, France Louis Labrousse
Leids Universitair Medisch Centrum, Leiden, The Netherlands Robert Klautz
NHS Foundation Trust - St Thomas’ Hospital, London, United Kingdom Vinayak Bapat
Herzzentrum Leipzig GmbH, Leipzig, Germany Michael Borger
Erasmus Medisch Centrum, Rotterdam, The Netherlands A. Pieter Kappetein
Klinikum und Fachbereich Medizin Johann Wolfgang Goethe, Frankfurt am Main, Germany Anton Moritz
Universit€atsklinikum K€oln - Anstalt des €offentlichen Rech, Cologne, Germany Thorsten Wahlers
Medizinische Hochschule Hannover, Hannover, Germany Malakh Lal Shrestha
Hôpital Bichat - Claude Bernard, Paris, France Patrick Nataf
Inselspital - Universit€atsspital Bern, Bern, Switzerland Thierry Carrel
Ospedale San Raffaele – Milano, Milan, Italy Ottavio Alfieri
Universit€atsSpital Z€urich, Zurich, Switzerland Volkmar Falk
Institut universitaire de cardiologie et pneumologie Quebec, Quebec, Canada François Dagenais
Toronto General Hospital, Toronto, Canada Vivek Rao
Ottawa Heart Institute, Ottawa, Canada Marc Ruel
Montreal Heart Institute, Montreal, Canada Raymond Cartier
The Toledo Hospital, Toledo, Ohio Michael Moront
Piedmont Atlanta Hospital, Atlanta, Ga Morris Brown
Mount Sinai Medical Center, New York, NY David Adams
University of Michigan Health System - University Hospital, Ann Arbor, Mich Himanshu Patel
Houston Methodist Hospital, Houston, Tex Michael Reardon
Heart Hospital of Austin, Austin, Tex John Oswalt
Aurora Saint Luke’s Medical Center, Milwaukee, Wis David Kress
University of Washington Medical Center, Seattle, Wash Gabriel Aldea
Abbott Northwestern Hospital, Minneapolis, Minn Vibhu Kshettry
Cleveland Clinic Foundation, Cleveland, Ohio Gosta Pettersson
OhioHealth Riverside Methodist Hospital, Columbus, Ohio Steve Duff
New York-Presbyterian Hospital/Columbia University Medical, New York, NY Michael Borger
University of Florida Health Shands Hospital, Gainesville, Fla Thomas Beaver
Massachusetts General Hospital, Boston, Mass Thoralf Sundt
Oklahoma Heart Hospital, Oklahoma City, Okla Goya Raikar
Maimonides Medical Center, Brooklyn, NY Greg Ribakove
University of Maryland Medical Center, Baltimore, Md James Gammie
University of Southern California University Hospital, Los Angeles, Calif Craig Baker
University of Colorado Hospital, Aurora, Colo David Fullerton
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TABLE E3. Objective performance criteria for heart valve substitutes
Rigid Flexible 2 3 OPC Late linearized event rate 95% upper bound of late linearized event rate
Thromboembolism 3.0 2.5 5.0 1.7 2.55
Valve thrombosis 0.8 0.2 0.4 0.0 0.00
All hemorrhage 3.5 1.4 2.8 3.6 4.81
Major hemorrhage 1.5 0.9 1.8 2.5 3.55
All PVL 1.2 1.2 2.4 0.6 1.18
Major PVL 0.6 0.6 1.2 0.0 0.00
Endocarditis 1.2 1.2 2.4 1.3 2.11
OPC and late linearized event rates are in% per patient-year. Late events include events that occurred more than 30 days postprocedure. Late linearized rates were calculated by
dividing the number of late events by the sum of the late patient-years of experience and expressed as a percentage. The OPC rates for valve-related events are defined by the
International Organization for Standardization 5840:2009 standards and the Food and Drug Administration heart valve guidance.E1,E2 OPC, Objective performance criteria;
PVL, paravalvular leak.
TABLE E2. Data collected at follow-up evaluations
Evaluation Data collected
Baseline*  Demographic information
 Medical history
 Pregnancy test for women of childbearing potential
 Physical examination
 NYHA functional classification
 Society of Thoracic Surgeons risk scores
 12-lead electrocardiogram




Implant  Procedure details, including condition of explanted valve and any additional procedures or interventions
 Valve data (ie, size, serial number, disposition of implanted valve, or opened packages)
 Device failure or malfunction
 Perioperative transesophageal echocardiography
 Relevant medications
 AEs or device deficiency
Discharge/30 d, 3-6 mo, 1 y,






 AEs or device deficiency
18 and 30 mo (via telephone)  Vital status
 Relevant medications
 AEs or device deficiency
AE, Adverse event; NYHA, New York Heart Association. *All baseline evaluations were completed within 45 days of the scheduled implant procedure except transthoracic
echocardiogram, which was required to be completed within 90 days of the procedure.
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TABLE E7. Late linearized rates with 95% upper bounds of all and



















Coumadin and aspirin 0.5 1.01











Coumadin and aspirin 0.1 0.47







AF, Atrial fibrillation; OPC, objective performance criteria. *Late events include
events that occurred >30 days postprocedure. Late linearized rates (% per
patient-year) were calculated by dividing the number of late events by the sum of
the late patient-years of experience and expressed as a percentage. yOPC rates are
provided as % per patient-year.












500 (57.9%) 480 (55.9%) 552 (68.1%) 427 (74.1%)




35 (4.1%) 282 (32.8%) 119 (14.7%) 48 (8.3%)
TABLE E5. Valve-related adverse events in patients aged less than
60 years at enrollment
Event No. of events No. of patients
Thromboembolism 4 3
Valve thrombosis 0 0
Major hemorrhage 1 1
Structural valve deterioration 0 0






TABLE E4. Additional procedural details
Characteristic
Patients
(N ¼ 864), (%)
Concomitant procedures
Coronary artery bypass grafting 281 (32.5)
Implantable cardiac device 1 (0.1)
LAA closure 66 (7.6)
PFO closure 10 (1.2)
Resection of subaortic membrane
not requiring myectomy
18 (2.1)
Ascending aortic aneurysm not
requiring circulatory arrest
64 (7.4)




Annular enlargement 11/341 (3.2)
Aortic root/STJ enlargement 56/344 (16.3)
Patch closure 29/344 (8.4)
Aortic root replacement 1/344 (0.3)
Other technique 26/344 (7.6)
Implanted valve size
17 mm 1 (0.1)
19 mm 39 (4.5)
21 mm 157 (18.2)
23 mm 314 (36.3)
25 mm 264 (30.6)
27 mm 80 (9.3)
29 mm 9 (1.0)
LAA, Left atrial appendage; PFO, patent foramen ovale; STJ, sinotubular junction.
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